AVISCERA BIOSCIENCE  
line decor
  HOME  ::  
line decor
   
 
PROPROTIN CONVERTASE 9 (PCSK9)
A New Target in Cardiovascular Therapeutics
Despite the efficacy of statin therapy, patients treated with these agents face substantial residual risk that is associated with achieved levels of LDL cholesterol (LDL-C). These observations suggest a potential benefit of additional strategies to promote further LDL-C reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as an attractive target in this regard. Abrogation of PCSK9 function prevents PCSK9-mediated catabolism of LDL receptors, increases cell surface LDL receptor density, and promotes clearance of LDL and other atherogenic lipoproteins from the circulation. Thus far, the most advanced approaches to block PCSK9 action are monoclonal antibodies and anti-sense oligonucleotides. Among statin-treated patients, these agents may produce additional LDL-C lowering exceeding 50 %. In rare genetic experiments of nature, individuals with dominant negative or dual loss of function mutations of PCSK9 appear to have no adverse health effects resulting from lifelong, very low levels of LDL-C. In short-term trials, PCSK9 antibodies have been generally well-tolerated. However, evidence to support long-term safety and efficacy of PCSK9therapy to reduce cardiovascular risk awaits the results of large cardiovascular outcome trials.
Do RQ, Vogel RA, Schwartz GG. Curr Cardiol Rep. 2013 Mar;15(3):345. doi: 10.1007/s11886-012-0345-z.

PCSK9: an emerging target for treatment of hypercholesterolemia

INTRODUCTION: Increased plasma low-density lipoprotein (LDL) cholesterol is a significant risk factor for cardiovascular disease. Plasma LDL-cholesterol is controlled through its uptake into cells upon binding the LDL receptor (LDLR). Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the LDLR and promotes its degradation, resulting in increased plasma LDL-cholesterol. Inhibiting the action of PCSK9 on the LDLR has emerged as a novel therapeutic target for hypercholesterolemia. AREAS COVERED: We briefly describe the identification and initial characterisation of PCSK9, before detailing the molecular mechanisms involved in its interaction with the LDLR. We highlight the potential sites for therapeutic intervention in this pathway and describe the current status of therapeutic approaches, including blocking antibodies, siRNA, antisense oligonucleotides and small-molecule inhibitors. The potential limitations of such approaches are also discussed. EXPERT OPINION: There is a wealth of evidence indicating that inhibition of PCSK9 is a highly desirable approach to combat hypercholesterolemia, with several agents in preclinical and clinical development. However, further research is required to fully understand the biological role of PCSK9 and whether its inhibition may have adverse effects in certain groups of patients, for example, those with liver disease.
Duff CJ, Hooper NM. Expert Opin Ther Targets. 2011 Feb;15(2):157-68
human pcsk9 elisa kit sk00003-01 enables to measure human samples. That is available in aviscera bioscience
 
 

Human PCSK9 ELISA Kit
Code No.:SK00003-01
Size: 96 T
Price:
Standard range: 62.5-4000 pg/ml
Sensitivity: 10 pg/ml
Specificity: human PCSK9
Sample type: serum, EDTA plasma
Dilution Factor: 100 ~ 200
Intra-CV: 4-6%
Inter-CV: 8-10%
Protein ID:Q8NBP7
Gene ID: 255738
Data Sheet: PDF
rat pcsk9 elisa kit sk00003-02
Rat PCSK9 ELISA Kit
Code No.:SK00003-02
Size: 96 T
Price:
Standard range:93-3000 pg/ml
Sensitivity: 50 pg/ml
Specificity: mouse PCSK9
Sample type: serum, EDTA plasma
Dilution Factor:
Intra-CV: 4-6%
Inter-CV: 8-10%
Data Sheet: PDF
mouse pcsk9 elisa kit from aviscera bioscience
Mouse PCSK9 ELISA Kit
Code No.:SK00003-04
Size: 96 T
Price:
Standard range:62-4000 pg/ml
Sensitivity: 30 pg/ml
Specificity: mouse PCSK9
Sample type: serum, EDTA plasma
Dilution Factor: 10
Intra-CV: 4-6%
Inter-CV: 8-10%
Data Sheet: PDF

Anti Human PCSK9 IgG
Code No.: A00003-01-100
Size: 100 ug
Price: $260.00 USD
Host: Rabbit
Antigen: human PCSK9 Rec.
Ab Type: Polyclonal IgG
Purification: Protein A
Applications: E, IHC (2-4 ug/ml)
Data Sheet: PDF
Anti Mouse PCSK9 IgG
Code No.: A00003-03-100
Size: 100 ug
Price: $260.00 USD
Host: Rabbit
Antigen: Mouse PCSK9 Rec.
Ab Type: Polyclonal IgG
Purification: Protein A
Applications: E, IHC (2-4 ug/ml)
Data Sheet: PDF
Name
Code No.
Size
Price ($)
PCSK9 (Human) ELISA Kit
96 T
PCSK9 (Rat) ELISA Kit
96 T
PCSK9 (Mouse) ELISA Kit
96 T
PCSK9 (Human), Rec.
00003-01-50
50 ug
250.00
PCSK9 (Human), Rec.
100 ug
360.00
PCSK9 (Human), Rec. .
00003-01-1000
1 mg
inquire
PCSK9 (Mouse), Rec.
100 ug
360.00
Rabbit Anti PCSK9 (Human) IgG
100 ug
260.00
Rabbit Anti PCSK9 (Mouse) IgG
100 ug
260.00
Anti Human PCSK9 Monoclonal Antibody
100 ug
260.00
Anti Human PCSK9 Monoclonal Antibody
100 ug
260.00
Anti Human PCSK9 Monoclonal Antibody
100 ug
260.00